James L. Gulley, M.D., Ph.D., F.A.C.P.
Laboratory of Tumor Immunology and Biology
Head, Clinical Trials Group
Deputy Laboratory Chief
National Cancer Institute
Building 10, Room 5B52
Bethesda, MD 20892
Phone: 301-435-2956
Fax: 301-480-1779
gulleyj@mail.nih.gov
Dr. James L. Gulley is a board certified medical oncologist. He is deputy chief of the Laboratory of Tumor Immunology and Biology (LTIB) at the National Cancer Institute (NCI) and director of the LTIB's Clinical Trials Group. He is a senior investigator within the Medical Oncology Branch. He received his medical training at Loma Linda University in its medical scientist training program, where he obtained a Ph.D. with his work in tumor immunology as well as an M.D. He went to Emory University for a residency in internal medicine and then to the National Cancer Institute for a fellowship in Medical Oncology. Following his fellowship, he was retained as senior staff at NCI.
Since 1999, Dr. Gulley has been involved in designing and running numerous clinical trials in prostate cancer at NCI. He has been an investigator on approximately 50 trials and has been the PI on 20. Most of the studies he has run use therapeutic vaccines for solid tumors. He has received multiple awards including, a shared NIH Group Merit Award “for major contributions to the field of cancer immunotherapy,” another NIH Group Merit Award “for making enormous strides in the treatment of several different stages of prostate cancer,” and the Presidential Early Career Award for Science and Engineering “for randomized, controlled studies using novel, recombinant vaccines to reduce the progression of prostate and other cancers and increase survival.” He has authored more than 150 original articles, reviews, and book chapters on immunotherapy and cancer treatments and has delivered numerous invited presentations at national and international meetings.
Dr. Gulley's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with breast cancer, prostate cancer, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.
Back to Top
